The use of apligraf in acute wounds

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Advances in the development of tissue engineered skin have led to several new products aimed at improving wound healing. Designed as a skin substitute, both epidermal and dermal equivalents have been under investigation and used clinically for over a decade. A novel bi-layered living skin equivalent, Apligraf, has been approved in several countries and is approval in the US FDA for the treatment of venous ulcers. Derived from foreskin, cultured neonatal fibroblasts are combined with bovine type I collagen to form a neodermis over which cultured neonatal keratinocytes are placed, proliferate and differentiate. In addition to use in venous ulcers, Apligraf use has also been reported in acute wounds such as surgical excision sites and partial thickness donor sites. Apligraf's use in acute wounds has lent insight into its biologic behavior, safety and efficacy. Through these experiences, it has been learned that Apligraf behaves similar to a partial thickness autograft, and is safe and effective. In addition, Apligraf appears to 'take', in many cases persists, is not clinically rejected but its ultimate fate is not known.

Original languageEnglish
Pages (from-to)805-811
Number of pages7
JournalJournal of Dermatology
Volume25
Issue number12
StatePublished - Dec 1 1998

Fingerprint

Wounds and Injuries
Varicose Ulcer
Skin
Artificial Skin
Foreskin
Autografts
Collagen Type I
Keratinocytes
Wound Healing
Fibroblasts
Apligraf
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

The use of apligraf in acute wounds. / Kirsner, Robert.

In: Journal of Dermatology, Vol. 25, No. 12, 01.12.1998, p. 805-811.

Research output: Contribution to journalArticle

Kirsner, Robert. / The use of apligraf in acute wounds. In: Journal of Dermatology. 1998 ; Vol. 25, No. 12. pp. 805-811.
@article{1f499bd9c5ef46b29e97238ff877e542,
title = "The use of apligraf in acute wounds",
abstract = "Advances in the development of tissue engineered skin have led to several new products aimed at improving wound healing. Designed as a skin substitute, both epidermal and dermal equivalents have been under investigation and used clinically for over a decade. A novel bi-layered living skin equivalent, Apligraf, has been approved in several countries and is approval in the US FDA for the treatment of venous ulcers. Derived from foreskin, cultured neonatal fibroblasts are combined with bovine type I collagen to form a neodermis over which cultured neonatal keratinocytes are placed, proliferate and differentiate. In addition to use in venous ulcers, Apligraf use has also been reported in acute wounds such as surgical excision sites and partial thickness donor sites. Apligraf's use in acute wounds has lent insight into its biologic behavior, safety and efficacy. Through these experiences, it has been learned that Apligraf behaves similar to a partial thickness autograft, and is safe and effective. In addition, Apligraf appears to 'take', in many cases persists, is not clinically rejected but its ultimate fate is not known.",
author = "Robert Kirsner",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "25",
pages = "805--811",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - The use of apligraf in acute wounds

AU - Kirsner, Robert

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Advances in the development of tissue engineered skin have led to several new products aimed at improving wound healing. Designed as a skin substitute, both epidermal and dermal equivalents have been under investigation and used clinically for over a decade. A novel bi-layered living skin equivalent, Apligraf, has been approved in several countries and is approval in the US FDA for the treatment of venous ulcers. Derived from foreskin, cultured neonatal fibroblasts are combined with bovine type I collagen to form a neodermis over which cultured neonatal keratinocytes are placed, proliferate and differentiate. In addition to use in venous ulcers, Apligraf use has also been reported in acute wounds such as surgical excision sites and partial thickness donor sites. Apligraf's use in acute wounds has lent insight into its biologic behavior, safety and efficacy. Through these experiences, it has been learned that Apligraf behaves similar to a partial thickness autograft, and is safe and effective. In addition, Apligraf appears to 'take', in many cases persists, is not clinically rejected but its ultimate fate is not known.

AB - Advances in the development of tissue engineered skin have led to several new products aimed at improving wound healing. Designed as a skin substitute, both epidermal and dermal equivalents have been under investigation and used clinically for over a decade. A novel bi-layered living skin equivalent, Apligraf, has been approved in several countries and is approval in the US FDA for the treatment of venous ulcers. Derived from foreskin, cultured neonatal fibroblasts are combined with bovine type I collagen to form a neodermis over which cultured neonatal keratinocytes are placed, proliferate and differentiate. In addition to use in venous ulcers, Apligraf use has also been reported in acute wounds such as surgical excision sites and partial thickness donor sites. Apligraf's use in acute wounds has lent insight into its biologic behavior, safety and efficacy. Through these experiences, it has been learned that Apligraf behaves similar to a partial thickness autograft, and is safe and effective. In addition, Apligraf appears to 'take', in many cases persists, is not clinically rejected but its ultimate fate is not known.

UR - http://www.scopus.com/inward/record.url?scp=0032462994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032462994&partnerID=8YFLogxK

M3 - Article

C2 - 9990773

AN - SCOPUS:0032462994

VL - 25

SP - 805

EP - 811

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 12

ER -